Parkinson's Disease Center and Movement Disorders Clinic

Click on the Expand plus sign sign to list the poster and platform presentations by year. Then click on the link to view that presentation.

2019

Collapse All | Expand All

 

    American Academy of Neurology (AAN)
    71st Annual Meeting in Philadelphia, Penn. (May 4-10, 2019)
    • Genome-wide association study meta-analysis for Parkinson disease motor subtypes.
      [Platform Presentation]

      Alfradique-Dunham I, Blauwendraat C, Al-Ouran R, von Coelln R, Tan M, Hill EJ, et al.

    • Immunogenicity of daxibotulinumtoxinA for injection in adults with cervical dystonia from a phase 2 dose-escalation multicenter study.

      Brashear A, Truong DD, Comella CL, Jankovic J, Patel AT, Prawdzik G, et al.

    • RECLAIM-DCP: A randomized, double-blind, placebo-controlled study of deutetrabenazine for the treatment of dyskinesia in cerebral palsy in children and adolescents.

      Claassen DO, Mink JW, Parnes M, Gordon MF, Barkay H, Wieman M, et al.

    • Long-term treatment with deutetrabenazine is associated with continued improvement in tardive dyskinesia (TD): Results from an open-label extension study.

      Hauser RA, Barkay H, Fernandez HH, Factor SA, Jimenez Shahed J, Gross N, et al.

    • Capturing Parkinson's disease heterogeneity with quantitative mobility measures.
      [Platform Presentation]

      Hill EJ, Alfradique-Dunham I, Mangleburg CG, Ripperger B, Stillwell A, Rao S, et al.

    • Activity-independent detection of mediation states in individuals with Parkinson's disease using wearable sensors.

      Hssayeni M, Burack M, Jimenez-Shahed J, Ghoraani B

    • Using a quality improvement framework to examine deep brain stimulation in Parkinson's disease: The RAD-PD initiative.

      Jimenez-Shahed J, d'Haese P-F, Kirk J, York MK, Berg A, Shih LC, et al.

    • STN LFP and SUA characterization of dyskinesia in PD using microelectrode recordings.

      Jimenez-Shahed J, Ozturk M, Kaku H, Viswanathan A, Ince N

    • Bradykinesia, mitochondrial myopathy and progressive ophthalmoplegia associated with a novel DNM1L mutation.

      Parnes M, Bashir HH, Jankovic J

    • Refractory gait freezing following GPi stimulation for Parkinson's disease.

      Sketchler B, Jimenez Shahed J

    Parkinson's Foundation
    Centers of Excellence Leadership Conference in Chandler, Ariz. (April 3-5, 2019)
    International Neuropsychological Society (INS)
    47th Annual Meeting in New York, N.Y. (Feb. 20-23, 2019)

2018

Collapse All | Expand All

 

    Huntington Study Group (HSG)
    Annual Meeting in Houston, Texas (Nov. 8-10, 2018)
    Movement Disorder Society (MDS)
    22nd International Congress of Parkinson's Disease and Movement Disorders in Hong Kong, China (Oct. 5-9, 2018)
    • Improvement in patient perceived quality of life with daxibotulinumtoxinA for injection in adults with cervical dystonia.

      Comella C, Brashear A, Jankovic J, Truong D, Patel A, Evatt M, et al.

    • Predictors of alcohol responsiveness in dystonia.

      Junker J, Brandt V, Berman B, Vidailhet M, Roze E, Weissbach A, et al.

    • Consensus for the measurement of the camptocormia angle.

      Margraf N, Wolke R, Granert O, Berardelli A, Berg D, Bloem B, et al.

    • Impact of dyskinesia in Parkinson's disease (PD) on activities of daily living (ADLs) and daily tasks: Results from pooled phase 3 ADS?5102 clinical trials.

      Pahwa R, Isaacson S, Jimenez?Shahed J, Malaty I, Deik A, Gandhy R, et al.

    • Integrated whole exome sequencing and chromosomal microarray in familial Parkinson's disease.

      Robak L, Du R, Yuan B, Gu S, Akdemir Z, Jankovic J, et al.

    • Accuracy of the International Parkinson Disease and Movement Disorder Society progressive supranuclear palsy diagnostic criteria (IPD-MDS-PSP).

      Shoeibi A, Litvan I, Juncos J, Bordelon Y, Riley D, Reich S, et al.

    • Genome-wide association study identifies common genetic variants associated with cervical dystonia.

      Sun Y, Hui Q, Perlmutter J, Ruehl S, Klein C, Jankovic J, et al.

    • Erotophonophilia and severe impulse control disorder in a patient with Parkinson's disease.

      vander Linden C, Colle H, Colle D, Jankovic J

    International Association of Parkinsonism and Related Disorders (IAPRD)
    XXIII World Congress on Parkinson's Disease and Related Disorders in Lyon, France. (Aug. 19-22, 2018)
    American Society for Stereotactic and Functional Neurosurgery (ASSFN)
    2018 Biennial Meeting in Denver, Colo. (June 2-5, 2018)
    • Developing a comprehensive quality improvement registry for DBS in Parkinson's disease.

      McInerney J, Jimenez-Shahed J, Farace E, Saunders-Pullman R, Schwalb JM, Shih L, et al.

    American Psychiatric Association (APA)
    171st Annual Meeting in New York City, N.Y. (May 5-9, 2018)
    • Long-term deutetrabenazine treatment response in tardive dyskinesia by concomitant dopamine-receptor antagonists and baseline comorbidities.

      Anderson K, Stamler D, Davis M, Hauser R, Jarskog L, Jimenez-Shahed J, et al.

    • Long-term improvements in site-rated outcomes with deutetrabenazine treatment in patients with tardive dyskinesia.

      Anderson K, Stamler D, Davis M, Hauser R, Jarskog L, Jimenez-Shahed J, et al.

    • Long-term treatment with deutetrabenazine improves quality of life in patients with tardive dyskinesia as assessed by a modified dystonia scale.

      Anderson K, Stamler D, Davis M, Hauser R, Jarskog L, Jimenez-Shahed J, et al.

    American Academy of Neurology (AAN)
    70th Annual Meeting in Los Angeles, Calif. (April 21-27, 2018)

2017

Collapse All | Expand All

 

    American Congress of Rehabilitation Medicine (ACRM)
    94th Annual Conference in Atlanta, Ga. (Oct. 23-28, 2017)
    Movement Disorder Society (MDS)
    21st International Congress of Parkinson's Disease and Movement Disorders in Vancouver, BC, Canada (June 4-8, 2017)
    • Whole exome sequencing in essential tremor.

      Alfradique-Dunham I, Robak LA, Kaw A, Fagbongbe OI, Ternes K, Young E, et al.

    • Effect of deutetrabenazine on QTcF interval in the AIM-TD study: A 12-week, phase III, randomized, double-blind, placebo-controlled study.

      Anderson K, Stamler D, Davis M, Factor S, Hauser R, Isojärvi J, et al.

    • Long-term safety of deutetrabenazine for the treatment of tardive dyskinesia: Results from an open-label, long-term study.
      [Previous presented]

      Anderson K, Stamler D, Davis M, Factor S, Hauser R, Isojärvi J, et al.

    • Addressing involuntary movements in tardive dyskinesia (aim-td): Efficacy, safety, and tolerability of fixed-dose deutetrabenazine for the treatment of tardive dyskinesia.
      [Previous presented]

      Anderson K, Stamler D, Davis M, Factor S, Hauser R, Isojärvi J, et al.

    • A phase 2, open-label, dose-escalating study to evaluate the safety and preliminary efficacy of daxibotulinumtoxinA for injection (RT002) in isolated cervical dystonia.
      [Previously Presented]

      Comella C, Jankovic J, Truong D, Brashear A, Patel A, Evatt M, et al.

    • Clinical relevance of treatment with onabotulinumtoxinA in patients with cervical dystonia: Results from the CD probe study.

      Dashtipour K, Mari Z, Jankovic J, Adler C, Schwartz M, Brin M

    • Effect of deutetrabenazine on quality of life in patients with tardive dyskinesia in AIM-TD, a 12-week double-blind, placebo-controlled study.
      [Previous presented]

      Factor S, Anderson K, Stamler D, Davis M, Hauser R, Isojärvi J, et al.

    • Effect of deutetrabenazine by body region score of the abnormal involuntary movement scale in tardive dyskinesia: ARM-TD and AIM-TD studies.
      [Previous presented]

      Fernandez H, Stamler D, Davis M, Factor S, Hauser R, Isojärvi J, et al.

    • Evaluation of patient-reported outcomes in tardive dyskinesia patients with underlying psychotic and mood disorders in the ARM-TD and AIM-TD trials.
      [Previous presented]

      Fernandez H, Stamler D, Davis M, Factor S, Hauser R, Isojärvi J, et al.

    • Improvements in clinical global impression of change with deutetrabenazine treatment in tardive dyskinesia from the ARM-TD and AIM-TD studies.
      [Previous presented]

      Fernandez H, Stamler D, Davis M, Factor S, Hauser R, Isojärvi J, et al.

    • Treatable rare movement disorders.

      Gatto E, Jinnah H, Espay A, Jankovic J, Bhatia K, Rodriguez M, et al.

    • A randomized, double-blind, placebo-controlled study of the D1 receptor antagonist ecopipam for children and adolescents with Tourette syndrome.

      Gilbert D, Murphy T, Jankovic J, Budman C, Black K, Kurlan R, et al.

    • Results from a phase 1b multiple ascending-dose study of prx002, an anti-alpha-synuclein monoclonal antibody, in patients with Parkinson's disease.

      Jankovic J, Goodman I, Safirstein B, Schenk D, Kinney G, Koller M, et al.

    • Leg stereotypy disorder: Phenomenology and prevalence.

      Jankovic J, Lotia M, York MK, Strutt AM

    • Addressing involuntary movements in tardive dyskinesia (AIM-TD): Improvements in clinical global impression of change (CGIC) with deutetrabenazine treatment in tardive dyskinesia (TD).
      [Previous presented]

      Jimenez-Shahed J, Fernandez H, Hauser R, Davis M, Factor S, Isojärvi J, et al.

    • Deutetrabenazine is associated with an improvement in involuntary movements in patients with tardive dyskinesia (TD) as seen by the high proportion of responders to deutetrabenazine treatment in the AIM-TD study.
      [Previous presented]

      Jimenez-Shahed J, Fernandez HH, Stamler D, Davis MD, Factor SA, Hauser RA, et al.

    • Deutetrabenazine treatment response by concomitant dopamine-receptor antagonists in the phase III, randomized, double-blind, placebo-controlled AIM-TD trial in tardive dyskinesia (TD).
      [Previous presented]

      Jimenez-Shahed J, Fernandez HH, Stamler D, Davis MD, Factor SA, Hauser RA, et al.

    • Emotion regulation and neuropsychological status in psychogenic subtypes.

      Scott B, Strutt A, Lundberg-Love P, Schmitt A, Jankovic J, Bowers D

    • Hemidystonia associated with Alexander disease.

      Vijayakumar D, Lewis RA, Fuller GN, Dhar SU, Machol K, Robak L, et al.

    American Psychiatric Association (APA)
    170th Annual Meeting in San Diego, Calif. (May 20-24, 2017)
    • Long-term safety of deutetrabenazine for the treatment of tardive dyskinesia: Results from an open-label, long-term study.

      Anderson K, Stamler D, Davis M, Factor S, Hauser R, Isojärvi J, et al.

    • Effect of deutetrabenazine on quality of life in patients with tardive dyskinesia in AIM-TD, a 12-week double-blind, placebo-controlled study.

      Factor S, Anderson K, Stamler D, Davis M, Hauser R, Isojärvi J, et al.

    • Effect of deutetrabenazine by body region score of the abnormal involuntary movement scale in tardive dyskinesia: ARM-TD and AIM-TD studies.

      Fernandez H, Stamler D, Davis M, Factor S, Hauser R, Isojärvi J, et al.

    • Evaluation of patient-reported outcomes in tardive dyskinesia patients with underlying psychotic and mood disorders in the ARM-TD and AIM-TD trials.

      Fernandez H, Stamler D, Davis M, Factor S, Hauser R, Isojärvi J, et al.

    • Improvements in clinical global impression of change with deutetrabenazine treatment in tardive dyskinesia from the ARM-TD and AIM-TD studies.

      Fernandez H, Stamler D, Davis M, Factor S, Hauser R, Isojärvi J, et al.

    American Academy of Neurology (AAN)
    69th Annual Meeting in Boston, Mass. (April 22-28, 2017)

<2016

Collapse All | Expand All